Bausch + Lomb vs Cytokinetics
Bausch + Lomb (BLCO), health care, and Cytokinetics (CYTK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bausch + Lomb is worth $7.4B on the stock market and Cytokinetics $7.2B: Bausch + Lomb is valued at 3% more. Bausch + Lomb's operating margin in its latest fiscal year was 2.22% and Cytokinetics's -695%. Over the past year Bausch + Lomb's share price has moved +38.3% and Cytokinetics's -19.6%.
Key facts
- Bausch + Lomb market value
- $7.4B
- Cytokinetics market value
- $7.2B
- Bausch + Lomb revenue
- $5.1BFY to 2025-12-31
- Cytokinetics revenue
- $88MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Bausch + Lomb | Cytokinetics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.4Bhigher | $7.2Blower |
| Revenue | $5.1Bhigher | $88Mlower |
| Earnings | -$360Mhigher | -$785Mlower |
| Employees | 13,000higher | 673lower |
| Total assets | $14Bhigher | $1.4Blower |
| Valuation | ||
| P/E | — | — |
| P/S | 1.5lower | 81.7higher |
| P/B | — | — |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 2.22%higher | -695%lower |
| Balance sheet | ||
| Net assets | $6.4Bhigher | -$659.6Mlower |
| Total liabilities | $7.5Bhigher | $2.1Blower |
| Total debt | $5Bhigher | $287.6Mlower |
| Cash on hand | $383Mhigher | $122.5Mlower |
| Price change | ||
| Today | -0.24%higher | -2.86%lower |
| 1 year | +38.3%higher | -19.6%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Bausch + Lomb only (4)
- Howard Marks1.1%
- Larry Robbins0.6%
- Carl Icahn0.4%
- Dan Loeb<0.1%
Cytokinetics only (3)
- Brandon Haley0.2%
- Steve Cohen0.2%
- Julian and Felix Baker0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns BLCO · Who owns CYTK
More on Bausch + Lomb
Further comparisons
Bausch + Lomb against its closest peers
Cytokinetics against its closest peers
Learn
Questions and answers
Which is bigger, Bausch + Lomb or Cytokinetics?
By market value, Bausch + Lomb is the larger: $7.4B against $7.2B for Cytokinetics. By revenue in its latest fiscal year, Bausch + Lomb is the larger: $5.1B against $88M for Cytokinetics.
Which has the higher operating margin?
Bausch + Lomb: 2.22%, against -695% for Cytokinetics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Bausch + Lomb: $5B, against $287.6M for Cytokinetics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Bausch + Lomb and Cytokinetics?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Bausch + Lomb and 3 hold Cytokinetics.
Cite this page
Funkfolio, “Bausch + Lomb vs Cytokinetics”, data as of 18 November 2026. https://funkfolio.com/compare/blco-vs-cytk
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.